EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, Mustafa Özgüroğlu, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Ho Gwo Fuang, Yaroslav Kulyaba und 12 weitere

Journal of Thoracic Oncology · 2025-07 · 20 (7) · 941-954

DOI: 10.1016/j.jtho.2025.03.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025-07. Verfasst von Saadettin Kilickap und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Türkiye. Electronic address: skilickap@yahoo.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, B7-H1 Antigen. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Earlier results from the phase 3 EMPOWER-Lung 1 trial indicated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for patients with advanced NSCLC with programmed cell death-ligand 1 (PD-L1) expression in 50% or more tumor cells and no EGFR, ALK, or ROS1 aberrations. Here, we report the five-year outcomes. METHODS: Patients were randomized 1:1 to cemiplimab 350 mg intravenously every three weeks for two years or the investigator's choice of chemotherapy. The primary endpoints were overall survival (OS) and progression-free survival. RESULTS: A total of 712 patients were randomized to cemiplimab (n = 357) or chemotherapy (n = 355). The median duration of follow-up was 59.6 months (interquartile range: 55.1-66.7 months) at the data cutoff (January 16, 2024). In patients with verified 50% or higher PD-L1 (n = 565), median OS was 26.1 months for cemiplimab versus 13.3 months for chemotherapy (hazard ratio = 0.59, 95% confidence interval [CI]: 0.48-0.72); the median progression-free survival was 8.1 months versus 5.3 months (hazard ratio = 0.50, 95% confidence interval: 0.41-0.61); and the objective response rate was 46.5% versus 20.6%. The five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy. Improved survival outcomes were observed with both squamous and nonsquamous histology, and increasing activity of cemiplimab was correlated with higher PD-L1 expression, with the highest PD-L1 expression having the best outcome. The safety profile remains consistent with previous results. Grade 3 or higher treatment-related adverse events occurred in 18.3% of patients for cemiplimab and 39.9% for chemotherapy. CONCLUSIONS: At five-year follow-up, first-line cemiplimab monotherapy continued to show durable clinical benefits versus chemotherapy in patients with advanced NSCLC with 50% or higher PD-L1. Patients with 90% or higher PD-L1 derived the largest clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedB7-H1 AntigenAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedSurvival RateFollow-Up StudiesAdult

Stichwörter der Autor:innen

CemiplimabLung neoplasmsNon–small cell lung cancerPD-L1Programmed cell death-ligand 1 inhibitor

Substanzen

Antibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humancemiplimabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Türkiye. Electronic address: skilickap@yahoo.com.
  • Acad. F. Todua Medical Center, Tbilisi, Georgia.
  • Department of Medical Oncology, Başkent University, Adana, Turkey.
  • Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Oncology, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
  • Department of Oncology and Medical Radiology, Dnipropetrovsk Medical Academy, Dnipro, Ukraine.

Förderung

  • Regeneron Pharmaceuticals Inc
  • Sanofi US

Zitieren

APA

Kilickap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Fuang, H. G., Kulyaba, Y., Zyuhal, K., Scheusan, R. I., Garassino, M. C., Li, Y., Zhu, C., Kaul, M., Perez, J., …, & Magnan, H. (2025). Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology, 20(7), 941-954. https://doi.org/10.1016/j.jtho.2025.03.033

Vancouver

Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology. 2025;20(7):941-954. doi:10.1016/j.jtho.2025.03.033

BibTeX
@article{Kilickap2025,
  author = {Kilickap, Saadettin and Baramidze, Ana and Sezer, Ahmet and Özgüroğlu, Mustafa and Gumus, Mahmut and Bondarenko, Igor and Gogishvili, Miranda and Nechaeva, Marina and Schenker, Michael and Cicin, Irfan and Fuang, Ho Gwo and Kulyaba, Yaroslav and Zyuhal, Kasimova and Scheusan, Roxana-Ioana and Garassino, Marina Chiara and Li, Yuntong and Zhu, Cong and Kaul, Manika and Perez, Javier and Seebach, Frank and Lowy, Israel and Pouliot, Jean-Francois and Kim, Eric and Magnan, Heather},
  title = {Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  volume = {20},
  number = {7},
  pages = {941--954},
  doi = {10.1016/j.jtho.2025.03.033}
}
Kostenlos starten →